Sigilon Therapeutics publishes engineered cells with reduced MHC expression for disease treatment.
The filing
Sigilon Therapeutics published a US application on November 12, 2026, describing engineered mammalian cells designed to treat disease. The application details cells engineered with a reduction in the level or function of major histocompatibility complex (MHC) class I protein complex components, and optionally MHC class II components or CIITA.
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.